{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T02:48:06Z","timestamp":1788144486626,"version":"build-2803163510"},"reference-count":122,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.annonc.2022.06.013","type":"journal-article","created":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T15:23:22Z","timestamp":1656429802000},"page":"893-908","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":94,"title":["Immunotherapy in unresectable stage III non-small-cell lung cancer: state of the art and novel therapeutic approaches"],"prefix":"10.1016","volume":"33","author":[{"given":"F.","family":"Cortiula","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Reymen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Van Mol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Wauters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Vansteenkiste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"De Ruysscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.E.L.","family":"Hendriks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annonc.2022.06.013_bib1","series-title":"AJCC Cancer Staging Manual","author":"Amin","year":"2017"},{"key":"10.1016\/j.annonc.2022.06.013_bib2","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/annonc\/mdx222","article-title":"Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Postmus","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2022.06.013_bib3","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1093\/annonc\/mdz175","article-title":"Current status of immune checkpoint inhibition in early-stage NSCLC","volume":"30","author":"Vansteenkiste","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2022.06.013_bib4","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2022.06.013_bib5","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non\u2013small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2022.06.013_bib6","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2022.06.013_bib7","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2022.06.013_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.586449","article-title":"Consolidation immunotherapy after platinum-based chemoradiotherapy in patients with unresectable stage III non-small cell lung cancer\u2014cross-sectional study of eligibility and administration rates","volume":"10","author":"Eichkorn","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.annonc.2022.06.013_bib9","article-title":"The impact of the availability of immunotherapy on patterns of care in stage III NSCLC: a Dutch Multicenter Analysis","volume":"2","author":"Ronden","year":"2021","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.annonc.2022.06.013_bib10","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.lungcan.2021.03.013","article-title":"Trends and variations in treatment of stage I-III non-small cell lung cancer from 2008 to 2018: a nationwide population-based study from the Netherlands","volume":"155","author":"Evers","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.annonc.2022.06.013_bib11","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.resinv.2019.03.011","article-title":"Patients with unresectable stage III non-small cell lung cancer eligible to receive consolidation therapy with durvalumab in clinical practice based on PACIFIC study criteria","volume":"57","author":"Sakaguchi","year":"2019","journal-title":"Respir Investig"},{"key":"10.1016\/j.annonc.2022.06.013_bib12","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1200\/JCO.2015.64.8824","article-title":"PROCLAIM: randomized phase III trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer","volume":"34","author":"Senan","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2022.06.013_bib13","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.radonc.2019.03.009","article-title":"Individualized accelerated isotoxic concurrent chemo-radiotherapy for stage III non-small cell lung cancer: 5-year results of a prospective study","volume":"135","author":"De Ruysscher","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.annonc.2022.06.013_bib14","doi-asserted-by":"crossref","first-page":"S939","DOI":"10.1016\/j.annonc.2021.08.1775","article-title":"1171MO PACIFIC-R real-world study: Treatment duration and interim analysis of progression-free survival in unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy","volume":"32","author":"Girard","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2022.06.013_bib15","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.1002\/cncr.33083","article-title":"A\u00a0phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN 14-179","volume":"126","author":"Durm","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.annonc.2022.06.013_bib16","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S1470-2045(21)00630-6","volume":"23","author":"Zhou","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2022.06.013_bib17","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1016\/j.annonc.2022.02.135","article-title":"108MO Safety and efficacy outcomes with durvalumab after sequential chemoradiotherapy (sCRT) in stage III, unresectable NSCLC (PACIFIC-6)","volume":"33","author":"Garassino","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2022.06.013_bib18","doi-asserted-by":"crossref","first-page":"6259","DOI":"10.3390\/cancers13246259","article-title":"Identification of potential prognostic and predictive immunological biomarkers in patients with stage I and stage III non-small cell lung cancer (NSCLC): a prospective exploratory study","volume":"13","author":"Vaes","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.annonc.2022.06.013_bib19","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2022.06.013_bib20","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2022.06.013_bib21","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.annonc.2022.06.013_bib22","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3389\/fonc.2018.00086","article-title":"Anti-PD-1 and Anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations","volume":"8","author":"Seidel","year":"2018","journal-title":"Front Oncol"},{"key":"10.1016\/j.annonc.2022.06.013_bib23","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1007\/s00262-012-1211-y","article-title":"Evaluation of CTLA-4 expression and relevance as a novel prognostic factor in patients with non-small cell lung cancer","volume":"61","author":"Salvi","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.annonc.2022.06.013_bib24","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1126\/science.1160062","article-title":"CTLA-4 control over Foxp3+ regulatory T cell function","volume":"322","author":"Wing","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.annonc.2022.06.013_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.662236","article-title":"Radiotherapy in the era of immunotherapy with a focus on non-small-cell lung cancer: time to revisit ancient dogmas?","volume":"11","author":"Khalifa","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.annonc.2022.06.013_bib26","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.8509","article-title":"Consolidation nivolumab plus ipilimumab or nivolumab alone following concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: BTCRC LUN 16-081","volume":"40","author":"Durm","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2022.06.013_bib27","doi-asserted-by":"crossref","first-page":"e264","DOI":"10.1016\/j.cllc.2021.07.005","volume":"23","author":"De Ruysscher","year":"2022","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.annonc.2022.06.013_bib28","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.it.2003.11.003","article-title":"Adenosine: an endogenous regulator of innate immunity","volume":"25","author":"Hask\u00f3","year":"2004","journal-title":"Trends Immunol"},{"key":"10.1016\/j.annonc.2022.06.013_bib29","doi-asserted-by":"crossref","DOI":"10.4161\/onci.22448","article-title":"The adenosinergic system in cancer: key therapeutic target","volume":"2","author":"Sorrentino","year":"2013","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.annonc.2022.06.013_bib30","doi-asserted-by":"crossref","first-page":"8738","DOI":"10.18632\/oncotarget.14434","article-title":"Prognostic impact of CD73 and A2A adenosine receptor expression in non-small-cell lung cancer","volume":"8","author":"Inoue","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.annonc.2022.06.013_bib31","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1002\/(SICI)1521-4141(199904)29:04<1076::AID-IMMU1076>3.0.CO;2-Z","article-title":"Differential regulation of killer cell Ig-like receptors and CD94 lectin-like dimers on NK and T lymphocytes from HIV-1-infected individuals","volume":"29","author":"Andr\u00e9","year":"1999","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.annonc.2022.06.013_bib32","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/(SICI)1521-4141(199901)29:01<23::AID-IMMU23>3.0.CO;2-Y","article-title":"Transforming growth factor-\u03b2-induced expression of CD94\/NKG2A inhibitory receptors in human T lymphocytes","volume":"29","author":"Bertone","year":"1999","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.annonc.2022.06.013_bib33","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.cell.2018.10.014","article-title":"Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells","volume":"175","author":"Andr\u00e9","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.annonc.2022.06.013_bib34","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.22.00227","article-title":"COAST: an open-label, phase II, multidrug platform study of durvalumab alone or in combination with oleclumab or monalizumab in patients with unresectable, stage III non\u2013small-cell lung cancer","author":"Herbst","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2022.06.013_bib35","article-title":"TIGIT in cancer immunotherapy","volume":"8","author":"Chauvin","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.annonc.2022.06.013_bib36","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.9503","article-title":"Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE)","volume":"38","author":"Rodriguez-Abreu","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2022.06.013_bib37","doi-asserted-by":"crossref","first-page":"S947","DOI":"10.1016\/j.annonc.2021.08.1794","volume":"32","author":"Dziadziuszko","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2022.06.013_bib39","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA8507","volume":"40","author":"Rudin","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2022.06.013_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.629722","article-title":"Tumor burden and immunotherapy: impact on immune infiltration and therapeutic outcomes","volume":"11","author":"Kim","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.annonc.2022.06.013_bib41","doi-asserted-by":"crossref","first-page":"5910","DOI":"10.1200\/JCO.2005.03.070","article-title":"Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d\u2019Oncologie Thoracique-Groupe Fran\u00e7ais de Pneumo-Canc\u00e9rologie NPC 95-01 Study","volume":"23","author":"Fournel","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2022.06.013_bib42","first-page":"e18","article-title":"Pembrolizumab plus chemotherapy in lung cancer","volume":"379","author":"Gandhi","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2022.06.013_bib43","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1056\/NEJMoa1613493","article-title":"First-line nivolumab in stage IV or recurrent non\u2013small-cell lung cancer","volume":"376","author":"Carbone","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2022.06.013_bib44","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1158\/2326-6066.CIR-15-0064","article-title":"The interplay of immunotherapy and chemotherapy: harnessing potential synergies","volume":"3","author":"Emens","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.annonc.2022.06.013_bib45","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.canlet.2018.08.028","article-title":"Immunogenic cell death in anticancer chemotherapy and its impact on clinical studies","volume":"438","author":"Wang","year":"2018","journal-title":"Cancer Lett"},{"key":"10.1016\/j.annonc.2022.06.013_bib46","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1007\/s00262-012-1307-4","article-title":"Chemotherapy broadens the range of tumor antigens seen by cytotoxic CD8(+) T cells in\u00a0vivo","volume":"61","author":"Jackaman","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.annonc.2022.06.013_bib47","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jtho.2020.09.027","article-title":"Neoadjuvant chemotherapy increases cytotoxic T cell, tissue resident memory T cell, and B cell infiltration in resectable NSCLC","volume":"16","author":"Gaudreau","year":"2021","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.annonc.2022.06.013_bib48","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/annonc\/mdy551","article-title":"Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors","volume":"30","author":"Heinhuis","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2022.06.013_bib49","doi-asserted-by":"crossref","first-page":"97920","DOI":"10.18632\/oncotarget.18542","article-title":"Changes in programmed death-ligand 1 expression during cisplatin treatment in patients with head and neck squamous cell carcinoma","volume":"8","author":"Ock","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.annonc.2022.06.013_bib50","article-title":"Upfront dose-reduced chemotherapy synergizes with immunotherapy to optimize chemoimmunotherapy in squamous cell lung carcinoma","volume":"8","author":"He","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.annonc.2022.06.013_bib51","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.lungcan.2019.05.001","article-title":"Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer\u2014the ETOP NICOLAS trial","volume":"133","author":"Peters","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.annonc.2022.06.013_bib52","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jtho.2020.10.129","volume":"16","author":"Peters","year":"2021","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.annonc.2022.06.013_bib53","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.jtho.2019.10.024","article-title":"Phase II trial of concurrent atezolizumab with chemoradiation for unresectable NSCLC","volume":"15","author":"Lin","year":"2020","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.annonc.2022.06.013_bib54","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.8508","article-title":"Two-year update from KEYNOTE-799: pembrolizumab plus concurrent chemoradiation therapy (cCRT) for unresectable, locally advanced, stage III NSCLC","volume":"40","author":"Reck","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2022.06.013_bib55","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.8512","volume":"39","author":"Jabbour","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2022.06.013_bib56","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1002\/bies.20085","article-title":"The PARP superfamily","volume":"26","author":"Am\u00e9","year":"2004","journal-title":"Bioessays"},{"key":"10.1016\/j.annonc.2022.06.013_bib57","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/S1470-2045(21)00531-3","article-title":"Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1\/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"22","author":"Banerjee","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2022.06.013_bib58","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1158\/2326-6066.CIR-15-0044","article-title":"CTLA-4 blockade synergizes therapeutically with PARP inhibition in BRCA1-deficient ovarian cancer","volume":"3","author":"Higuchi","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.annonc.2022.06.013_bib59","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.bbrc.2015.05.083","article-title":"The PARP1 inhibitor BMN 673 exhibits immunoregulatory effects in a Brca1(-\/-) murine model of ovarian cancer","volume":"463","author":"Huang","year":"2015","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.annonc.2022.06.013_bib60","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1158\/1078-0432.CCR-16-3215","article-title":"PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression","volume":"23","author":"Jiao","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2022.06.013_bib61","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S1470-2045(20)30324-7","article-title":"Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1\/2, basket study","volume":"21","author":"Domchek","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2022.06.013_bib62","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1158\/2159-8290.CD-16-0577","article-title":"Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease","volume":"6","author":"Liu","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.annonc.2022.06.013_bib63","doi-asserted-by":"crossref","DOI":"10.1126\/science.aax0182","article-title":"Neoadjuvant checkpoint blockade for cancer immunotherapy","volume":"367","author":"Topalian","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.annonc.2022.06.013_bib64","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2174\/157339406777934717","article-title":"Cancer therapy-induced residual bone marrow injury-Mechanisms of induction and implication for therapy","volume":"2","author":"Wang","year":"2006","journal-title":"Curr Cancer Ther Rev"},{"key":"10.1016\/j.annonc.2022.06.013_bib65","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.3390\/cancers13061468","article-title":"Charged particle and conventional radiotherapy: current implications as partner for immunotherapy","volume":"13","author":"Marcus","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.annonc.2022.06.013_bib66","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1038\/s41467-018-03730-x","article-title":"Multi-omics analysis reveals neoantigen-independent immune cell infiltration in copy-number driven cancers","volume":"9","author":"McGrail","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.annonc.2022.06.013_bib67","doi-asserted-by":"crossref","first-page":"5558","DOI":"10.1158\/1078-0432.CCR-14-1138","article-title":"Galectin-1 mediates radiation-related lymphopenia and attenuates NSCLC radiation response","volume":"20","author":"Kuo","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2022.06.013_bib68","doi-asserted-by":"crossref","first-page":"137R","DOI":"10.1093\/glycob\/cwl025","article-title":"Galectin-1: a small protein with major functions","volume":"16","author":"Camby","year":"2006","journal-title":"Glycobiology"},{"key":"10.1016\/j.annonc.2022.06.013_bib69","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1038\/sj.onc.1211029","article-title":"Galectin-1, a novel ligand of neuropilin-1, activates VEGFR-2 signaling and modulates the migration of vascular endothelial cells","volume":"27","author":"Hsieh","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.annonc.2022.06.013_bib70","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nri.2017.145","article-title":"Improving immune\u2013vascular crosstalk for cancer immunotherapy","volume":"18","author":"Huang","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.annonc.2022.06.013_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2021.104298","article-title":"Radiotherapy and cGAS\/STING signaling: impact on MDSCs in the tumor microenvironment","volume":"362","author":"Kho","year":"2021","journal-title":"Cell Immunol"},{"key":"10.1016\/j.annonc.2022.06.013_bib72","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.3390\/cancers13061191","article-title":"Linking serine\/glycine metabolism to radiotherapy resistance","volume":"13","author":"S\u00e1nchez-Castillo","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.annonc.2022.06.013_bib73","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.8513","article-title":"AFT-16: Phase II trial of neoadjuvant and adjuvant atezolizumab and chemoradiation (CRT) for stage III non-small cell lung cancer (NSCLC)","volume":"39","author":"Ross","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2022.06.013_bib74","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1832760","article-title":"Immunotherapy as sensitizer for local radiotherapy","volume":"9","author":"Vanneste","year":"2020","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.annonc.2022.06.013_bib75","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non\u2013small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2022.06.013_bib76","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.8510","article-title":"The selective personalized radio-immunotherapy for locally advanced NSCLC Trial (SPRINT): initial results","volume":"40","author":"Ohri","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2022.06.013_bib77","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1186\/s12885-020-07406-y","article-title":"A\u00a0phase II study of daily carboplatin plus irradiation followed by durvalumab for stage III non-small cell lung cancer patients with PS 2 up to 74 years old and patients with PS 0 or 1 from 75 years: NEJ039A (trial in progress)","volume":"20","author":"Kaira","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.annonc.2022.06.013_bib78","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS8585","article-title":"Thoracic radiotherapy PLUS durvalumab in elderly and\/or frail NSCLC stage III patients unfit for chemotherapy: employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy\u2014The TRADE-hypo trial","volume":"39","author":"Bozorgmehr","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2022.06.013_bib79","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/annonc\/mdz167","article-title":"Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry","volume":"30","author":"Mazieres","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2022.06.013_bib80","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ejca.2022.02.015","article-title":"Who benefits from consolidation durvalumab in stage III non-small cell lung cancer?","volume":"167","author":"De Ruysscher","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annonc.2022.06.013_bib81","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ejca.2022.02.014","article-title":"Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations","volume":"167","author":"Riudavets","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annonc.2022.06.013_bib82","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.jtho.2021.01.1628","article-title":"Durvalumab for stage III EGFR-mutated NSCLC after definitive chemoradiotherapy","volume":"16","author":"Aredo","year":"2021","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.annonc.2022.06.013_bib83","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.lungcan.2022.01.020","article-title":"Treatment patterns and outcomes in early-stage ALK-rearranged non-small cell lung cancer","volume":"166","author":"Schmid","year":"2022","journal-title":"Lung Cancer"},{"key":"10.1016\/j.annonc.2022.06.013_bib84","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ctrv.2018.10.006","article-title":"Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: is the time ripe for a change?","volume":"71","author":"Remon","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.annonc.2022.06.013_bib85","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1093\/annonc\/mdz077","article-title":"Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib","volume":"30","author":"Schoenfeld","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2022.06.013_bib86","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.annonc.2022.02.003","article-title":"ESMO expert consensus statements on the management of EGFR mutant non-small cell lung cancer","volume":"33","author":"Passaro","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2022.06.013_bib88","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/annonc\/mdy553","article-title":"Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP)","volume":"30","author":"Peters","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2022.06.013_bib89","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1158\/2159-8290.CD-17-0716","article-title":"Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling","volume":"7","author":"Chaudhuri","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.annonc.2022.06.013_bib90","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.561598","article-title":"Circulating tumor DNA as a prognostic biomarker in localized non-small cell lung cancer","volume":"10","author":"Peng","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.annonc.2022.06.013_bib91","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s43018-019-0011-0","article-title":"Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer","volume":"1","author":"Moding","year":"2020","journal-title":"Nat Cancer"},{"key":"10.1016\/j.annonc.2022.06.013_bib92","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nm.3519","article-title":"An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage","volume":"20","author":"Newman","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.annonc.2022.06.013_bib93","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1158\/2159-8290.CD-21-0634","article-title":"Detecting liquid remnants of solid tumors: circulating tumor DNA minimal residual disease","volume":"11","author":"Moding","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.annonc.2022.06.013_bib94","author":"Neal"},{"key":"10.1016\/j.annonc.2022.06.013_bib95","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","article-title":"Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden","volume":"378","author":"Hellmann","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2022.06.013_bib96","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/s41591-020-01211-7","article-title":"Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma","volume":"27","author":"Rozeman","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.annonc.2022.06.013_bib97","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1126\/science.aaf2834","article-title":"The \u201ccancer immunogram\u201d","volume":"352","author":"Blank","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.annonc.2022.06.013_bib98","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.annonc.2021.09.021","article-title":"Distinct tumor-infiltrating lymphocyte landscapes are associated with clinical outcomes in localized non-small-cell lung cancer","volume":"33","author":"Federico","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2022.06.013_bib99","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.lungcan.2021.07.008","article-title":"Prognostic and predictive value of PD-L1 expression and tumor infiltrating lymphocytes (TiLs) in locally advanced NSCLC treated with simultaneous radiochemotherapy in the randomized, multicenter, phase III German Intergroup lung Trial (GILT)","volume":"160","author":"Tufman","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.annonc.2022.06.013_bib100","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s00330-020-07141-9","article-title":"Radiomics in predicting treatment response in non-small-cell lung cancer: current status, challenges and future perspectives","volume":"31","author":"Chetan","year":"2021","journal-title":"Eur Radiol"},{"key":"10.1016\/j.annonc.2022.06.013_bib101","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2967\/jnumed.112.107375","article-title":"Are pretreatment 18F-FDG PET tumor textural features in non-small cell lung cancer associated with response and survival after chemoradiotherapy?","volume":"54","author":"Cook","year":"2013","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.annonc.2022.06.013_bib102","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0207455","article-title":"A\u00a0radiomic approach for adaptive radiotherapy in non-small cell lung cancer patients","volume":"13","author":"Ramella","year":"2018","journal-title":"PloS One"},{"key":"10.1016\/j.annonc.2022.06.013_bib103","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.3054","article-title":"Novel imaging biomarkers predict progression-free survival in stage 3 NSCLC treated with chemoradiation and durvalumab","volume":"39","author":"Jazieh","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2022.06.013_bib104","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157836","article-title":"Early change in metabolic tumor heterogeneity during chemoradiotherapy and its prognostic value for patients with locally advanced non-small cell lung cancer","volume":"11","author":"Dong","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.annonc.2022.06.013_bib105","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.ijrobp.2018.05.053","article-title":"Repeatability and reproducibility of radiomic features: a systematic review","volume":"102","author":"Traverso","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.annonc.2022.06.013_bib106","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.radonc.2013.05.007","article-title":"Selection of patients for radiotherapy with protons aiming at reduction of side effects: the model-based approach","volume":"107","author":"Langendijk","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.annonc.2022.06.013_bib107","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-95643-x","article-title":"Prediction of radiation pneumonitis after definitive radiotherapy for locally advanced non-small cell lung cancer using multi-region radiomics analysis","volume":"11","author":"Kawahara","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.annonc.2022.06.013_bib108","article-title":"Biomarkers of checkpoint inhibitor induced immune-related adverse events-a comprehensive review","volume":"10","author":"Hommes","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.annonc.2022.06.013_bib109","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s10637-017-0524-2","article-title":"Radiomics to predict immunotherapy-induced pneumonitis: proof of concept","volume":"36","author":"Colen","year":"2018","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.annonc.2022.06.013_bib110","doi-asserted-by":"crossref","first-page":"e1822","DOI":"10.1002\/onco.13900","article-title":"Radiation versus immune checkpoint inhibitor associated pneumonitis: distinct radiologic morphologies","volume":"26","author":"Chen","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.annonc.2022.06.013_bib111","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/mp.15451","article-title":"Differentiation between immune checkpoint inhibitor-related and radiation pneumonitis in lung cancer by CT radiomics and machine learning","volume":"49","author":"Cheng","year":"2022","journal-title":"Med Phys"},{"key":"10.1016\/j.annonc.2022.06.013_bib112","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.cell.2021.02.011","article-title":"Understanding and treating the inflammatory adverse events of cancer immunotherapy","volume":"184","author":"Dougan","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.annonc.2022.06.013_bib113","doi-asserted-by":"crossref","first-page":"4305","DOI":"10.1172\/JCI128654","article-title":"The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis","volume":"129","author":"Suresh","year":"2019","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.annonc.2022.06.013_bib114","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/s41571-020-0352-8","article-title":"Moving towards personalized treatments of immune-related adverse events","volume":"17","author":"Esfahani","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.annonc.2022.06.013_bib115","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1186\/s12885-020-06893-3","article-title":"CD73 blockade enhances the local and abscopal effects of radiotherapy in a murine rectal cancer model","volume":"20","author":"Tsukui","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.annonc.2022.06.013_bib116","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.594212","article-title":"Stereotactic body radiotherapy is effective in modifying the tumor genome and tumor immune microenvironment in non-small cell lung cancer or lung metastatic carcinoma","volume":"11","author":"Zhou","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.annonc.2022.06.013_bib117","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3390\/ijms20010024","article-title":"Combining radiotherapy and immunotherapy in lung cancer: can we expect limitations due to altered normal tissue toxicity?","volume":"20","author":"Wirsd\u00f6rfer","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.annonc.2022.06.013_bib118","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1158\/2326-6066.CIR-14-0196","article-title":"Stereotactic radiation therapy augments antigen-specific PD-1\u2013mediated antitumor immune responses via cross-presentation of tumor antigen","volume":"3","author":"Sharabi","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.annonc.2022.06.013_bib119","doi-asserted-by":"crossref","first-page":"e498","DOI":"10.1016\/S1470-2045(15)00007-8","article-title":"Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy","volume":"16","author":"Sharabi","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2022.06.013_bib120","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ijrobp.2016.02.022","article-title":"Tumor cells surviving exposure to proton or photon radiation share a common immunogenic modulation signature, rendering them more sensitive to T cell-mediated killing","volume":"95","author":"Gameiro","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.annonc.2022.06.013_bib121","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1084\/jem.20052494","article-title":"Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy","volume":"203","author":"Reits","year":"2006","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.annonc.2022.06.013_bib122","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/S1470-2045(09)70082-8","article-title":"Systemic effects of local radiotherapy","volume":"10","author":"Formenti","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2022.06.013_bib123","doi-asserted-by":"crossref","first-page":"959","DOI":"10.3390\/ijms20040959","article-title":"Realizing the clinical potential of immunogenic cell death in cancer chemotherapy and radiotherapy","volume":"20","author":"Rapoport","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.annonc.2022.06.013_bib124","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.immuni.2014.10.019","article-title":"STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors","volume":"41","author":"Deng","year":"2014","journal-title":"Immunity"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753422017422?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753422017422?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T06:14:10Z","timestamp":1760336050000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753422017422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":122,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S0923753422017422"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2022.06.013","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapy in unresectable stage III non-small-cell lung cancer: state of the art and novel therapeutic approaches","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2022.06.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 European Society for Medical Oncology. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}